Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$4.16
-0.02 (-0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $1.6B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.1B
P/E
13.9x
↓EV/EBITDA
9.1x
↓ROE
2.9%
↑Gross Margin
31.8%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.5%
FCF CAGR
—
FCF margin
29.1%
FCF / Net income
4.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.48B · net income $349.5M · FCF $1.59B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.48B | $5.48B | $5.28B | $5.45B | $7.16B |
| Net Income | $349.5M | $349.5M | $646.7M | $-783.3M | $727.4M |
| EBITDA | $846.6M | $846.6M | $1.20B | $-331.5M | $1.37B |
| EPS | 0.24 | 0.24 | 0.44 | -0.53 | 0.50 |
| Gross Margin | 31.8% | 31.8% | 33.3% | 33.1% | 32.6% |
| Operating Margin | 11.6% | 11.6% | 14.1% | 11.8% | 15.7% |
| Net Margin | 6.4% | 6.4% | 12.2% | -14.4% | 10.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.29 | 0.47 | 0.52 |
| Current Ratio | 2.15 | 2.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.59B | $1.59B | $1.99B | $-46.7M | $-979.0M |
| Returns | |||||
| ROE | 2.9% | 2.9% | 5.3% | -6.6% | 5.9% |
| Valuation | |||||
| P/E | 13.87 | 13.87 | 8.58 | — | 11.36 |
| EV/EBITDA | 9.13 | 9.13 | 6.18 | — | 9.17 |
| P/B | 0.51 | 0.51 | 0.46 | 0.42 | 0.67 |
| Growth & Yield | |||||
| Revenue Growth | 3.8% | 3.8% | -3.0% | -23.9% | — |
| EPS Growth | -46.0% | -46.0% | 182.6% | -207.7% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.7%
EPS terminal req.
$0.37
Spread vs growth
-61.7%
5Y implied EPS CAGR
13.4%
EPS terminal req.
$0.45
Spread vs growth
-59.4%
10Y implied EPS CAGR
11.7%
EPS terminal req.
$0.72
Spread vs growth
-57.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.0%
Start / end P/E
10.1x → 17.5x
EPS bridge
0.44 → 0.24
Residual
-33.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.